S&P 500 Industrials Sector SEC Filings — March 11, 2026

11-03-2026

LaFayette Acquisition Corp., a SPAC, filed its 10-K annual report outlining its focus on acquisition targets with enterprise values of $500M to $1.5B, fundamentally sound financials, and positive cash flows. The filing highlights risks such as potential insider loans up to $1.5M convertible into units at $10.00 per unit, conflicts of interest, and impacts from debt or share issuances. Financial statements cover the year ended December 31, 2025, and the period from inception (June 7, 2024) through December 31, 2024, but specific performance metrics are not detailed in the provided content.

• ·Company inception date: June 7, 2024
• ·Financial statements include Balance Sheets as of December 31, 2025 and 2024; Statements of Operations, Changes in Shareholders’ Deficit, and Cash Flows for year ended December 31, 2025 and period from inception through December 31, 2024
• ·Potential non-interest bearing loans from initial shareholders or affiliates for transaction costs, with no written agreements yet

11-03-2026

Yotta Acquisition Corporation terminated its Business Combination Agreement, dated August 20, 2024, with DRIVEiT Financial Auto Group, Inc. and other parties, effective March 4, 2026, by providing written notice pursuant to Article 10. No separate termination agreement was entered into, ending the previously disclosed merger plans. This development represents a setback for the SPAC's primary business combination objective.

• ·Securities registered: Units (YOTAU), Common Stock (YOTA), Warrants (YOTAW), Rights (YOTAR) on Nasdaq Stock Market LLC
• ·Company is an emerging growth company

11-03-2026

Boxabl Inc. appointed Shanmugam 'Shan' Palaniappan as Chief Technology Officer on March 10, 2026, to bolster software, automation, and AI capabilities as it advances toward a merger with FG Merger II Corp., per the agreement signed August 4, 2025. The move supports Boxabl's transition to an industrial-scale housing manufacturer, with no financial metrics disclosed. Forward-looking statements highlight potential benefits but note risks including merger approval delays and redemptions.

• ·Boxabl founded in 2017.
• ·Merger Agreement dated August 4, 2025, involves two-step merger with FG Merger Sub II Inc.; FGMC to become Surviving Pubco named BOXABL Inc.
• ·FGMC IPO prospectus filed January 29, 2025; Boxabl 10-K filed April 14, 2025.

11-03-2026

Flutter Entertainment plc filed an 8-K on March 11, 2026, under Items 7.01 and 9.01, disclosing an RNS Announcement regarding its share repurchase program, released via the Regulatory News Service in London to comply with UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules. The announcement is furnished as Exhibit 99.1. No specific financial metrics, amounts, or performance data were detailed in the filing.

11-03-2026

Target Hospitality reported FY2025 revenue of $320.6M, down 17% YoY from $386.3M, net loss of $37.1M versus $71.4M profit, and Adjusted EBITDA of $53.2M, a 73% decline from $196.7M, primarily due to the PCC Contract termination effective February 2025, with utilization dropping to 51% from 83%. Q4 revenue increased 7% YoY to $89.8M from $83.7M, driven by new Workforce Hub and Dilley Contracts, but Adjusted EBITDA fell to $6.5M from $41.1M. The company secured over $740M in multi-year contracts since February 2025, including new $129M West Texas Power Community (1,400 beds) and $23M Pecos Power Community (400 beds), with 2026 outlook of $320-330M revenue and $60-70M Adjusted EBITDA.

• ·Zero net debt and $8M cash as of Dec 31, 2025.
• ·FY2026 outlook: Capital Expenditures $65-75M, excluding acquisitions.
• ·HFS-South Q4 utilization 69% vs 73% YoY.
• ·Government segment Q4 adjusted gross profit $5.4M vs $37.7M YoY.
• ·WHS segment Q4 revenue $39.7M (new) with $9.1M adjusted gross profit.

11-03-2026

Serve Robotics reported strong revenue growth with Q4 2025 at $0.9M (up ~400% YoY from $0.2M) and full year 2025 at $2.7M (exceeding $2.5M guidance and up 46% YoY from $1.8M), scaling fleet to 2,000 robots across 20 cities in 6 metro areas while achieving 99.8% delivery completion. However, net losses widened dramatically to $101M for full year 2025 from $39M in 2024, with Q4 loss at $34M amid surging operating expenses ($97M vs $38M prior year) and gross losses. The company raised 2026 revenue guidance to $26M and maintained $260M liquidity, bolstered by four strategic acquisitions diversifying into healthcare and AI.

• ·Daily Active Robots increased to 547 in Q4 2025 from 312 in Q3 2025 and 257 in Q4 2024.
• ·Recurring revenues grew over 4x from ~$0.2M in Q1 2025 to over $0.8M in Q4 2025.
• ·Software services revenue: $1.0M full year 2025 vs $1.2M in 2024 (slight decline).
• ·Net cash used in operating activities: $80M for both full year 2025 and 2024.

11-03-2026

Ironwood Pharmaceuticals, Inc. notified Wells Fargo Bank, as administrative agent, on March 10, 2026, that it satisfied the liquidity conditions under the Credit Agreement dated May 21, 2023 (as amended September 27, 2024). As a result, the maturity date for the revolving credit facility remains December 31, 2028, subject to other terms and conditions.

• ·Credit Agreement originally dated May 21, 2023, and amended by Amendment No. 1 on September 27, 2024.
• ·Filing signed and dated March 11, 2026.

11-03-2026

Ryder System, Inc. filed a DEFA14A Definitive Additional Proxy Materials on March 11, 2026, as soliciting material under Rule 240.14a-12. The filing indicates no fee was required and contains no substantive financial data, metrics, or performance details. This appears to be supplemental proxy information ahead of a shareholder meeting.

11-03-2026

Vistagen Therapeutics, Inc. implemented a Board-approved 20% workforce reduction on March 5, 2026, aimed at disciplined cash management while prioritizing the PALISADE Program clinical studies for fasedienol in social anxiety disorder. The company anticipates immaterial costs from severance and benefits, with a cash runway extending into 2027, though additional unforeseen costs may arise. Topline results from the PALISADE-4 Phase 3 trial are expected in the first half of 2026.

• ·Affected employees may receive cash severance and temporary healthcare coverage upon signing a separation agreement with general release of claims.
• ·Filing date: March 11, 2026.
• ·Costs incurred expected to be immaterial, but additional costs may occur due to associated events.

11-03-2026

Janus Henderson Group plc (JHG) has filed a DEFM14A proxy statement seeking shareholder approval at a special meeting on April 16, 2026, for a merger agreement signed on December 21, 2025, with Parent and Merger Sub, under which shareholders will receive $49.00 per share in cash, and JHG will become a wholly owned subsidiary of Parent, ceasing to be publicly traded. The merger requires a two-thirds majority of votes cast and is expected to complete mid-2026, subject to conditions including regulatory approvals. Trian funds own approximately 20.23% of shares as of May 1, 2025, with no financial performance metrics reported.

• ·No dissenting shareholders’ appraisal rights available; however, shareholders may apply to the Royal Court of Jersey within 21 days post-approval if merger unfairly prejudices interests.
• ·Special meeting at 9:00 a.m. Denver time on April 16, 2026; record date precedes meeting.
• ·Brokers lack discretionary voting authority on merger proposal.

11-03-2026

Unity Bancorp, Inc. filed a supplement to its definitive proxy statement dated March 6, 2026, solely to correct a typographical error on page 4 regarding diluted EPS disclosure, amending it from three months ending December 31, 2025, to full-year diluted EPS. No other changes were made to the original proxy statement, which remains in effect for the Annual Meeting of Stockholders on April 23, 2026. This filing does not introduce new financial data or performance metrics.

• ·Original proxy statement filed with SEC on March 6, 2026.
• ·Supplement dated March 10, 2026; filing date March 11, 2026.
• ·Address: 64 Old Highway 22, Clinton, NJ 08809

11-03-2026

Kewaunee Scientific reported Q3 FY26 sales of $69.4M, up 3.3% YoY from $67.2M, driven by strong 21.4% growth in the International segment to $18.4M, though Domestic sales declined 2.0% to $51.0M. Pre-tax earnings rose 25.8% to $1.6M and EBITDA was relatively flat at $3.8M, but net earnings fell to $0.7M from $1.4M with diluted EPS at $0.23 versus $0.45 YoY, amid lower manufacturing volumes and a reduced order backlog of $183.2M (down 17.3% YoY from $221.6M).

• ·YTD nine months FY26 net sales $210.6M (adjusted), up from adjusted $163.3M prior year.
• ·Corporate segment pre-tax net loss $3.1M, relatively flat YoY.
• ·Long-term debt net of sale-leaseback $16.3M, down from $34.1M at April 30, 2025.
• ·Nu Aire acquisition closed November 1, 2024.

11-03-2026

Strategic Education, Inc. (STRA) filed Definitive Additional Proxy Materials (DEFA14A) on March 11, 2026, for its virtual Annual Meeting of Stockholders on April 22, 2026, at 8:00 A.M. ET. Key proposals include the election of 12 directors, ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, and advisory approval of named executive officer compensation. The Board recommends voting 'FOR' all proposals, with proxy materials available online and voting options via internet.

• ·Paper/email copy requests due by April 14, 2026
• ·Virtual meeting registration deadline: April 18, 2026 at 11:59 P.M. ET
• ·Voting via www.AALvote.com/STRA using 11-digit Virtual Control Number

11-03-2026

Triumph Financial, Inc.'s 2026 Proxy Statement discloses 2025 executive compensation for five NEOs, with CEO Aaron P. Graft's total pay rising 31% YoY to $4.6M driven by higher stock awards ($2.81M), while non-equity incentive compensation fell 2% YoY to $363K and has declined 20% from 2023 levels. Other NEOs saw total comp increases of 20-41% YoY to $1.3M-$2.3M, but non-equity incentives were flat or down slightly (e.g., COO Edward J. Schreyer -2% to $250K). Stock grants on May 1, 2025, used $54.38/share closing price and Black-Scholes $28.35/option.

• ·Stock option exercise price $54.38 and Black-Scholes value $28.35 per share for May 1, 2025 grants.
• ·Performance-based RSU Monte Carlo valuations: $86.87/target share (bank peers), $97.43/target share (fintech peers).
• ·All NEOs received $14,000 401(k) match in 2025; CEO club memberships $54,618.
• ·Assuming max performance, 2025 PSUs valued at $4.44M for CEO at $54.38/share.
• ·10-K for year ended Dec 31, 2025 filed Feb 11, 2026.

11-03-2026

Oragenics, Inc. received final Human Research Ethics Committee (HREC) approval in Australia on March 10, 2026, to commence its Phase IIa clinical trial of lead drug candidate ONP-002 for concussion and mild traumatic brain injury (mTBI). The company announced on March 11, 2026, that it is exploring discussions with third parties for potential acquisition of additional assets in the central nervous system (CNS) space. On March 12, 2026, Oragenics completed the first site initiation visit (SIV) for the Phase IIa trial of ONP-002 in Australia.

11-03-2026

UWM Holdings Corporation is pursuing the acquisition of Two Harbors Investment Corp (TWO), offering enhanced scale with a pro forma market cap of ~$7.6B (7x TWO standalone), $2.2B float, and complementary origination-servicing capabilities. UWM reported Q4 2025 origination volume of $49.6B, its highest in 4 years with Gain on Sale margins up 17bps YoY, and projects Q1 2026 revenue of $800M-$900M and FY2026 revenue of $3.5B-$4.5B. The deal promises ~$150M cost synergies and TWO's board endorsement, though subject to risks like integration challenges and market conditions.

• ·UWM has issued quarterly dividend of $0.10 per share every quarter since 2021.
• ·TWO unaffected stock price of $9.91 as of 12/16/2025.
• ·Analyst consensus price target $6.00 implying 49% upside from current $4.04 stock price (3/10/2026); recent high $6.10 (1/16/2026), 52-week high $7.14.

11-03-2026

TechTarget, Inc. reported revenues of $486.8M for FY 2025, up 71% YoY from $284.9M in 2024, driven by 105% growth in marketing, advertising services, and sponsorship to $355.8M and 51% increase in advisory services to $52.4M, though intelligence subscriptions grew only 3% to $77.0M. However, a $931.5M goodwill impairment charge propelled operating expenses up 345% to $1.32B and resulted in a $1.01B net loss, worsening 763% from $116.9M in 2024. Total assets declined sharply to $937.3M from $2.27B, with cash dropping to $40.6M.

• ·Net cash provided by operating activities improved to $16.3M in FY 2025 from ($64.9M) in FY 2024.
• ·Convertible debt eliminated to $0 at Dec 31, 2025 from $415.7M at Dec 31, 2024.
• ·Related party long-term debt increased to $106.7M at Dec 31, 2025 from $0.
• ·Restructuring costs of $14.7M in FY 2025.
• ·Basic and diluted net loss per share $14.06 in FY 2025 vs $2.65 in FY 2024.

11-03-2026

Comtech Telecommunications Corp. held its Fiscal 2025 Annual Meeting of Stockholders on March 9, 2026, electing all seven director nominees to the Board, though Mark R. Quinlan and Lawrence J. Waldman each received approximately 1.5M votes against amid total votes cast of around 38M. Stockholders also approved the advisory vote on named executive officer compensation (32.0M for vs. 5.6M against), ratified Deloitte & Touche LLP as the independent auditor for fiscal year ending July 31, 2026 (44.2M for), and approved an amendment to the 2023 Equity and Incentive Plan to increase available shares (37.1M for). All proposals passed consistent with Board recommendations, with broker non-votes around 6.1M.

• ·Proposal No. 2 votes: For 32,033,498; Against 5,598,343; Abstain 769,161
• ·Proposal No. 4 votes: For 37,122,608; Against 1,165,014; Abstain 113,382; Broker Non-Votes 6,134,311
• ·Kenneth H. Traub director votes: For 38,123,051; Against 259,978; Abstain 17,979

11-03-2026

Guardian Pharmacy Services, Inc. reported revenue of $1.45B for the year ended December 31, 2025, up 17.9% YoY from $1.23B in 2024, driven by gross profit growth to $293M. SG&A expenses fell 28.4% to $220M (15.2% of revenue vs. 25.0% prior year), swinging operating income to $73M from a $63M loss and net income attributable to $49M from a $110M loss; however, cost of goods sold as a percentage of revenue slightly improved to 79.8% from 80.1%. Adjusted EBITDA increased to $115M from $91M.

• ·Executive officers each have more than 30 years of experience in the pharmacy industry.
• ·Team began working together in 1993 on a previous pharmacy venture acquired by Bindley Western in 1999.
• ·Net income attributable to Guardian Pharmacy, LLC prior to Corporate Reorganization: $23M in 2024.
• ·Net income (loss) attributable to non-controlling interests: $16M in 2024 and -$0.3M in 2025.

11-03-2026

Graphic Packaging Holding Company appointed Jeffrey M. Stafeil to its Board of Directors effective March 8, 2026, as a Class I Director with term expiring in 2026. Mr. Stafeil is an independent director not yet assigned to any board committee and has no related party transactions requiring disclosure under Item 404(a) of Regulation S-K. The appointment was reported in an 8-K filing dated March 11, 2026.

• ·Company headquartered at 1500 Riveredge Parkway, Atlanta, Georgia 30328.
• ·Common Stock trades on New York Stock Exchange under symbol GPK.

11-03-2026

Codexis, Inc. reported total revenues of $70.4M for the year ended December 31, 2025, up 19% YoY from $59.3M, primarily driven by R&D revenue surging 97% to $44.4M; however, product revenue declined sharply 29% to $26.0M. Net loss narrowed to $44.0M from $65.3M, with total operating expenses down 5% to $112.1M amid lower cost of product revenue (-43%) but higher R&D expenses (+13%). Product gross margin improved to 64% from 56% YoY.

• ·Net cash used in operating activities improved to $(19.4M) in 2025 from $(49.4M) in 2024.
• ·Net cash provided by financing activities was $27.9M in 2025.
• ·Restructuring charges of $3.4M recorded in 2025.
• ·Working capital at $71.5M as of Dec 31, 2025, down slightly from $75.1M in 2024.

11-03-2026

STONERIDGE INC filed an 8-K on 2026-03-11 reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, with Item 9.01 providing financial statements and exhibits. This is a multi-item mandatory disclosure with no specific transaction details, dollar values, or financial impacts disclosed. No positive or negative metrics are provided.

11-03-2026

Descartes Systems Group Inc. filed its Form 40-F Annual Report for the fiscal year ended January 31, 2026, incorporating audited consolidated financial statements, MD&A, and annual information form, with 86,024,747 common shares outstanding as of period-end. The company completed multiple acquisitions including Three Gtms (March 2025), Packageroute Holdco Inc. (June 2025), and others, alongside Fiscal 2026 and 2025 restructuring plans. Audit fees from KPMG LLP were nearly flat, declining slightly by 0.2% to $957,095 from $958,873 in FY2025.

• ·No off-balance sheet arrangements material to investors.
• ·No changes in internal control over financial reporting during FY2026.
• ·All audit committee members designated as financial experts.
• ·Tax fees and all other fees to KPMG LLP were $Nil for both FY2026 and FY2025.

11-03-2026

Lakewood-Amedex Biotherapeutics Inc. (LABT) filed Amendment No. 3 to its S-1 registration statement on March 11, 2026, for the resale of up to 4,689,177 shares of common stock by Registered Stockholders via a direct listing on Nasdaq Capital Market, with no proceeds to the company. The company engaged RBW Capital Partners LLC as financial advisor (to receive 271,762 shares as 1.75% compensation) and placement agent for a $7.5M private placement of 937,500 shares of Series C Preferred Stock at $10.00 per share through Dawson James Securities. Listing is contingent on Nasdaq approval, with potential volatility noted due to the novel direct listing structure.

• ·RBW engagement agreement executed February 10, 2025.
• ·Series C conversion price: lower of $10.00 or 80% of 5-day avg closing price, floor $1.00.
• ·Resale registration for Series C underlying common stock and advisory shares to be filed within 10 days of Nasdaq listing.
• ·Company is emerging growth company and smaller reporting company.
• ·Nevada incorporation, SIC 2834 (Pharmaceutical Preparations), EIN 20-5274304, CIK 0002079272.

11-03-2026

Target Corp's FY2025 net sales declined 1.7% YoY to $104.8B from $106.6B, with comparable sales down 2.6% due to 2.2% lower traffic and 0.4% lower average transaction amount. Operating income fell 8.1% to $5.1B, GAAP diluted EPS decreased 8.2% to $8.13, and gross margin rate slipped to 27.9% from 28.2%, while SG&A expense rate remained flat at 20.6%. Adjusted operating income dropped 14.2% to $4.8B amid business transformation costs and interchange fee settlements.

• ·Depreciation and amortization expense increased 3.5% YoY to $2,617M in FY2025.
• ·Gross margin rate declined to 27.9% from 28.2% in FY2024.
• ·Adjusted SG&A expenses decreased 0.4% to $21,877M in FY2025.

11-03-2026

Lattice Semiconductor Corporation (LSCC) announced the resignation of Tonya Stevens, its Chief Accounting Officer, submitted on March 11, 2026, and effective March 29, 2026. The resignation is explicitly stated to not be due to any disagreement with the company's operations, policies, or practices. The 8-K filing was signed by Tracy Feanny, Senior Vice President and General Counsel.

• ·Filing type: 8-K (Items 5.02, 9.01)
• ·Registrant details: Delaware incorporation, Commission File Number 000-18032, IRS EIN 93-0835214, principal offices at 5555 NE Moore Court, Hillsboro, Oregon 97124

11-03-2026

EDUCATIONAL DEVELOPMENT CORP filed an 8-K on March 11, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No details on the agreement terms, parties involved, transaction value, strategic rationale, or financial impacts are provided in the filing summary. Specific quantitative metrics, period-over-period comparisons, or guidance changes are NOT_DISCLOSED.

11-03-2026

Global Payments Inc. entered into an Underwriting Agreement on March 5, 2026, with Barclays Capital Inc., BofA Securities, Inc., and J.P. Morgan Securities LLC as representatives of the underwriters to issue $500M aggregate principal amount of 4.550% Senior Notes due 2028 and $500M of 5.400% Senior Notes due 2033, totaling $1B in a public offering. The offering is expected to close on March 12, 2026, subject to customary closing conditions. The notes are registered under Registration Statement on Form S-3 (No. 333-291270) filed November 5, 2025.

• ·Underwriting Agreement contains customary representations, warranties, indemnification, and termination provisions.
• ·Notes registered pursuant to Registration Statement on Form S-3 (No. 333-291270).
• ·Company's common stock (GPN) and 4.875% Senior Notes due 2031 (GPN31A) listed on New York Stock Exchange.

11-03-2026

Baker Hughes successfully priced a $6.5B USD senior notes offering in five tranches and a €3B senior notes offering in four tranches, with net proceeds intended to fund a portion of the cash consideration for its proposed acquisition of Chart Industries. The notes, issued by subsidiaries Baker Hughes Holdings LLC and Baker Hughes Holdings Co-Obligor, Inc., are fully guaranteed by Baker Hughes on a senior unsecured basis, with closing expected on March 11, 2026. A special mandatory redemption at 101% of principal applies if the Chart acquisition does not consummate.

• ·Pricing announced March 5, 2026; closing subject to customary conditions on March 11, 2026
• ·Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC as joint global coordinators for USD offering; similar roles for EUR offering
• ·Offerings pursuant to effective shelf registration with SEC

11-03-2026

Community West Bancshares reported net income of $38.2M for the year ended December 31, 2025, up 398% YoY from $7.7M in 2024, driven by net interest income growth to $136.2M (+23% YoY) and sharply lower provisions for credit losses ($3.8M vs. $11.1M). However, average investment securities balances declined to $825M (-10% YoY) with yields dropping to 2.79%, and nonaccrual loans rose to $6.5M average. ROE improved to 9.92% from 2.42% but remained below 2023's 13.81%, while efficiency ratio was 61.63%.

• ·Allowance for credit losses on loans: $30.1M at Dec 31, 2025 (up from $25.8M at Dec 31, 2024)
• ·Non-interest bearing deposits: $1.06B at Dec 31, 2025 (up 8% YoY)
• ·Interest rate sensitivity: NII +3.73% in Year 1 for +400 bps shock, but -2.60% for -400 bps shock

11-03-2026

Corbus Pharmaceuticals Holdings, Inc. (CRBP), a pharmaceutical preparations company (SIC 2834), filed an S-3 registration statement on March 11, 2026, enabling a shelf registration for potential future securities offerings under the Securities Act of 1933. The filing, sized at 2 MB with Acc-no: 0001193125-26-102396, reflects standard capital access preparation amid recent activity including multiple 13G filings indicating institutional ownership updates and prior financial reports. No quantitative financial metrics, period comparisons, or performance changes (positive, negative, or flat) are detailed in this procedural filing.

• ·CIK: 0001595097
• ·Business Address: 500 River Ridge Drive, Norwood, MA 02062
• ·State of Incorporation: DE
• ·Fiscal Year End: December 31

11-03-2026

Alpha Pro Tech Ltd reported consolidated net sales of $59.1M for 2025, up 2.2% YoY from $57.8M, driven by 2.3% growth in US sales to $58.5M, though international sales declined 2.2% to $0.6M. Operating income improved 11.3% to $3.8M with margins expanding to 6.5% from 6.0%, but gross profit fell 1.7% to $22.5M (margin 38.1% vs 39.6%) and net income decreased 10.1% to $3.5M (margin 6.0% vs 6.8%). Cash and equivalents dropped to $17.0M from $18.6M, with operating cash flow declining sharply to $2.4M from $5.7M.

• ·Common stock repurchased and retired: 685,313 shares in 2025 for $3.3M (vs 831,000 shares for $4.5M in 2024).
• ·Accounts receivable, net increased 87.9% to $6.9M from $3.7M.
• ·Equity in income of unconsolidated affiliate dropped to $0.2M from $0.6M.
• ·Basic EPS $0.34 in 2025 vs $0.35 in 2024.

11-03-2026

Telecom Argentina reported revenues of P$8.3B for 2025, up 53.0% YoY from P$5.4B, with Adjusted EBITDA increasing 64.8% to P$2.5B, reflecting strong operational growth including a shift to positive operating income of P$450M from a prior loss. However, the company swung to a net loss of P$145M from a P$1.4B profit in 2024, driven by sharply deteriorated financial results from borrowings (P$-749M vs P$1.9B gain), while total capital expenditures rose significantly to P$1.7B including right-of-use assets. Inbound international visitors declined 19.7% in 2025, though inbound roaming revenue increased 15.7%.

• ·Depreciation, amortization and impairment increased 20.3% YoY to P$2.1B.
• ·Financial results from borrowings deteriorated to P$-749M from P$1.9B gain.
• ·TMA Network capex (PP&E and intangibles) rose to P$456.6M from P$95.3M in 2024.

11-03-2026

Biogen Inc. announced on March 11, 2026, that Susan H. Alexander, its Chief Legal Officer, will depart effective at the end of May 2026. The company has initiated a search for a successor to fill the Chief Legal Officer position. No details were provided on the reasons for departure or any compensatory arrangements.

• ·Biogen Inc. (CIK: 0000875045, EIN: 33-0112644) is incorporated in Delaware with principal offices at 225 Binney Street, Cambridge, MA 02142.
• ·Common Stock ($0.0005 par value) trades as BIIB on Nasdaq Global Select Market.

11-03-2026

Advantage Solutions Inc., through its subsidiary Advantage Sales & Marketing Inc., entered into the Third Amendment to its ABL Revolving Credit Agreement on March 11, 2026, extending the Maturity Date of the Revolving Facility and amending various schedules, exhibits, and related security agreements. The amendment facilitates reallocation of Revolving Commitments among consenting lenders and replacement of non-consenting lenders, with no outstanding loans post-effective date. No specific financial metrics, improvements, or declines were disclosed in the filing.

• ·Original ABL Revolving Credit Agreement dated October 28, 2020; prior amendments on October 28, 2021 (First) and December 2, 2022 (Second).
• ·Effectiveness subject to execution by required parties, payment of fees/expenses to agents and arrangers, and delivery of officer certificates, organization documents, and legal opinions.

11-03-2026

Bridger Aerospace Group Holdings, Inc. announced the retirement of CFO Eric Gerratt effective March 10, 2026, with a transition period until April 3, 2026, including a $180,000 retention fee and continued vesting of RSUs. Anne Hayes, previously Deputy CFO, was appointed as the new CFO effective the same date, retaining her $500,000 annual base salary and $150,000 bonus eligibility. Separately, Adolphus 'Bill' Andrews was appointed COO effective March 2, 2026, with a $400,000 salary, $160,000 bonus potential, and $1M in RSU awards.

• ·Eric Gerratt previously announced resignation on November 21, 2025.
• ·Anne Hayes served as Deputy CFO since November 2025 and on Board from September 2023 to November 2025 as Audit Committee Chair.
• ·Adolphus Andrews appointment announced March 4, 2026; RSUs vest one-third annually for 2026 award and 50% immediate/50% at one-year for inducement.
• ·Anne Hayes is a CPA with BS Finance from Villanova University and MS Finance from University of Denver.

11-03-2026

SunPower Inc. entered into a Purchase Agreement on March 6, 2026, issuing a $10M principal convertible debenture to YA II PN, LTD. for a $9M purchase price (90% of principal), providing immediate funding but with mandatory installment repayments starting May 6, 2026, potential 18% default interest, and conversion rights into common stock at $2.50 per share or 95% VWAP, posing significant dilution risk capped at 22.4M shares. Concurrently, the company amended its prior Sunder Note with Chicken Parm Pizza LLC, extending maturity if needed and increasing interest to 10% post-May 15, 2026. These transactions highlight liquidity support amid restrictive terms and Nasdaq-compliant ownership limits of 4.99%.

• ·Debenture maturity: March 6, 2027 (extendable at Investor's option)
• ·Installment Dates: May 6, June 6, July 6, August 6, September 6, 2026
• ·Fixed conversion price: $2.50 per share
• ·Optional redemption allowed only if VWAP < $2.50, with 3% premium (waived before April 30, 2026)
• ·Sunder Note extended maturity potentially to September 30, 2026 or December 31, 2026

11-03-2026

Devon Energy Corporation shared a preliminary post-close organizational structure for its proposed merger with Coterra Energy Inc., assigning responsibilities to key executives such as Blake Sirgo (Operations), Shane Young (Chief Financial Officer), and John Raines and Michael DeShazer (E&P EVPs) to enhance performance and maximize synergies. The structure covers areas like legal, HR, drilling, subsurface, business development, E&P operations, finance, technology, and new ventures, but remains subject to future refinements with decisions on senior roles and locations to be announced at closing. Devon and Coterra continue operating independently until transaction close, with a Form S-4 registration statement and joint proxy statement/prospectus forthcoming.

• ·Filing date: March 11, 2026
• ·Devon 10-K for FY2025 filed February 18, 2026
• ·Coterra 10-K for FY2025 filed February 27, 2026
• ·Devon definitive proxy for 2025 AGM filed April 23, 2025
• ·Coterra definitive proxy for 2025 AGM filed March 20, 2025

11-03-2026

GalaxyEdge Acquisition Corporation, a Cayman Islands-incorporated SPAC, consummated its IPO on March 5, 2026, selling 10,000,000 units at $10.00 each, generating $100M in gross proceeds. Simultaneously, sponsor Equinox Capital Solutions Limited purchased 220,000 private placement units at $10.00 each for $2.2M in gross proceeds. $100M of net proceeds were deposited into a trust account maintained by Continental Stock Transfer & Trust Company.

• ·Securities listed on The New York Stock Exchange
• ·Audited balance sheet as of March 5, 2026 included as Exhibit 99.1
• ·Emerging growth company status confirmed

11-03-2026

First Internet Bancorp reported net interest income growth of 30% YoY to $113.8M for 2025, driven by higher interest-earning assets ($5.66B average) and improved net interest margin of 2.01%, up from 1.65% in 2024. However, total assets declined to $5.57B from $5.74B, loans decreased 10% to $3.75B, noninterest income plunged 94% to $2.7M due to an $8.3M loss on loan sales, and nonperforming loans ratio deteriorated to 1.56% from 0.68%. Noninterest expenses rose 5% to $95.0M amid higher salaries and premises costs.

• ·Nonaccrual loans increased to $56.4M from $26.0M at Dec 31 2024.
• ·Allowance for credit losses to loans: 1.49% (2025) vs 1.07% (2024).
• ·Interest-bearing deposits average balance up to $4.87B from $4.32B YoY.

11-03-2026

Heritage Commerce Corp announced its regular quarterly cash dividend of $0.13 per share on March 11, 2026. The dividend will be paid on April 8, 2026, to shareholders of record at the close of business on March 25, 2026. This routine declaration signals stable financial health with no comparative financial metrics provided.

• ·Filing includes Exhibit 99.1: Press Release dated March 11, 2026, entitled 'Heritage Commerce Corp Declares Regular Quarterly Cash Dividend of $0.13 Per Share'

11-03-2026

On March 5, 2026, the Audit Committee of Diodes Incorporated dismissed Baker Tilly US, LLP as its independent registered public accounting firm effective immediately, with no adverse opinions, disagreements, or reportable events during fiscal years ended December 31, 2025 and 2024, or the subsequent interim period through March 5, 2026. The Audit Committee engaged PricewaterhouseCoopers LLP (PwC) as the new independent registered public accounting firm for the fiscal year ending December 31, 2026, with no prior consultations on accounting principles, audit opinions, or reportable events. Baker Tilly provided a concurring letter dated March 11, 2026, filed as Exhibit 16.1.

• ·The dismissal and engagement were approved by the Audit Committee of the Board of Directors.
• ·Securities: Common Stock, Par Value $0.66 2/3, trading as DIOD on Nasdaq Stock Market LLC.

11-03-2026

Quoin Pharmaceuticals Ltd. (QNRX) announced on March 11, 2026, that the FDA granted Fast Track Designation to QRX003 lotion (4%) for treating Netherton Syndrome, a rare genetic skin disorder with no approved therapies. The Fast Track program facilitates expedited development through frequent FDA interactions, rolling review eligibility, and potential Accelerated Approval or Priority Review. No financial impacts or comparative metrics were disclosed.

11-03-2026

First Community Bancshares, Inc. (FCBC) filed Definitive Additional Proxy Materials (DEFA14A) with the SEC on March 11, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and was submitted by the registrant. No specific financial data, shareholder proposals, or other substantive details are provided in the available filing content.